Dexrazoxane Can Mediate Cardiotoxicity in Childhood Cancer Survivors

Survivors of childhood cancers are at significantly increased risk of cardiotoxicity if treated with anthracyclines, according to a new review of the literature. That toxicity, though, can be substantially ameliorated if dexrazoxane is administered before each anthracycline dose.

Read more here: http://www.cancernetwork.com/news/dexrazoxane-can-mediate-cardiotoxicity-childhood-cancer-survivors